low-dose CNS-penetrant BACE inhibitor

90% red. of CSF A_ in Ph. II at 9.2 mg / discont.

from opt. vs. CatD and dose red. of prior leads

Journal of Medicinal Chemistry

Eli Lilly, Indianapolis, US

6. The Lilly beta-site APP cleaving enzyme (BACE) inhibitor LY3202626 is an oral, low-dose, CNS-penetrant molecule which entered a Phase II of clinical trial against AlzheimerĂ•s disease in 2016.…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.